Cohort Study for the Assessment of Long-term Impact of COVID-19 Among Mild COVID-19 Patients in Brazil

Utility score of health related quality of life at 3, 6, and 9 months

The outcome will be assessed using the Brazilian version of the Euroqol-5D-3L (EQ-5D3L) questionnaire. The utility score derived from the EQ5D-3L ranges from 0 (death) to 1 (perfect health).

Time frame: The outcome will be assessed at 3, 6, and 9 months after enrollment.

Incidence of all-cause mortality

Incidence of all-cause mortality

Time frame: The outcome will be assessed at 1, 3, 6, 9, and 12 months after enrollment.

Incidence of major cardiovascular events

Incidence of major cardiovascular events (composite endpoint of non-fatal stroke, non-fatal acute myocardial infarction, or cardiovascular death)

Time frame: The outcome will be assessed at 3, 6, 9, and 12 months after enrollment.

Incidence of hospitalizations

Incidence of all-cause hospitalizations

Time frame: The outcome will be assessed at 1, 3, 6, 9, and 12 months after enrollment.

Prevalence of prolonged COVID-19 symptoms

Prevalence of prolonged COVID-19 symptoms defined as presence of dyspnea, cough, fatigue, muscular weakness, chest discomfort, joint pain, anosmia, hair loss, brain fog, insomnia, among others)

Time frame: The outcome will be assessed at 1, 3, 6, 9, and 12 months after enrollment.

Prevalence of cognitive dysfunction

Prevalence of cognitive dysfunction as assessed by the Telephone Interview for Cognitive Status (TICS-m; scores ranging from 0 to 50 with lower scores indicating worse cognition).

Time frame: The outcome will be assessed at 3, 6, 9, and 12 months after enrollment.

Prevalence of anxiety and depression symptoms

Prevalence of anxiety and depression symptoms as assessed by the Hospital Anxiety and Depression Scale (anxiety and depression scores range from 0 to 21, with higher scores indicating worse symptoms).

Time frame: The outcome will be assessed at 3, 6, 9, and 12 months after enrollment.

Prevalence of posttraumatic stress disorder symptoms

Prevalence of posttraumatic stress disorder symptoms as assessed by the Impact Event Scale-6 (scores range from 0 to 24 with higher scores indicating worse symptoms).

Time frame: The outcome will be assessed at 3, 6, 9, and 12 months after enrollment.

Physical functional status

Physical functional status as assessed by the modified Barthel index (score ranges from 0 to 100; higher scores indicate less functional dependence).

Time frame: The outcome will be assessed at 3, 6, 9, and 12 months after enrollment.

Instrumental Activities of Daily Living

The outcome will be assessed using the Lawton \& Brody Instrumental Activities of Daily Living Scale (the score ranges from 0 to 8, with higher scores indicating less dependence).

Time frame: The outcome will be assessed at 3, 6, 9, and 12 months after enrollment.

Incidence of return to work or study

Incidence of return to work or study among patients that were working or studying at the moment of COVID-19 diagnosis.

Time frame: The outcome will be assessed at 3, 6, 9, and 12 months after enrollment.

Incidence of new symptomatic COVID-19 infection

Incidence of new symptomatic COVID-19 infection defined as recurrence of COVID-19-related symptoms with a positive PCR test for SARS-CoV-2 90 days after the index infection.

Time frame: The outcome will be assessed at 3, 6, 9, and 12 months after enrollment.